The CHMP noted that, when Halaven was used as a third-line therapy for breast cancer (after at least two previous treatments with cancer medicines for advanced/metastatic disease), it prolonged the length of time that patients lived and the safety profile is within what is expected for chemotherapy medicines. What benefit has Halaven shown during the studies? Halaven was compared with dacarbazine (another cancer medicine), and the main measure of effectiveness was overall survival. Halaven was also studied in 143 patients with liposarcoma who had previously undergone at least two other treatments, which included an anthracycline. The main measures of effectiveness were overall survival and progression-free survival (how long the patients lived without their disease getting worse). The study compared Halaven with capecitabine (another cancer medicine). The second study involved 1,102 patients with advanced or metastatic breast cancer, with one or two previous treatments for advanced/metastatic cancer including an anthracycline and a taxane. The main measure of effectiveness was overall survival (how long the patients lived). The women were given either Halaven or another approved cancer medicine chosen by their doctor. In the first study, Halaven was compared with other treatments in 762 women with advanced or metastatic breast cancer, who had previously undergone at least two other treatments, which included an anthracycline and a taxane. In breast cancer, Halaven was studied in two main studies involving a total of 1,864 patients.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |